238 related articles for article (PubMed ID: 25050888)
1. FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels.
Chen L; Luo LF; Lu J; Li L; Liu YF; Wang J; Liu H; Song H; Jiang H; Chen SJ; Luo C; Li KK
PLoS One; 2014; 9(7):e103033. PubMed ID: 25050888
[TBL] [Abstract][Full Text] [Related]
2. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
[TBL] [Abstract][Full Text] [Related]
3. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
Yang Y; Huang Q; Lu Y; Li X; Huang S
J Cell Biochem; 2012 Apr; 113(4):1314-22. PubMed ID: 22109829
[TBL] [Abstract][Full Text] [Related]
4. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.
Gao XN; Lin J; Ning QY; Gao L; Yao YS; Zhou JH; Li YH; Wang LL; Yu L
PLoS One; 2013; 8(2):e55481. PubMed ID: 23390536
[TBL] [Abstract][Full Text] [Related]
5. Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia.
Estella-Hermoso de Mendoza A; Castello-Cros R; Imbuluzqueta E; Cirauqui C; Pippa R; Odero MD; Blanco-Prieto MJ
J Biomed Nanotechnol; 2015 Apr; 11(4):691-701. PubMed ID: 26310075
[TBL] [Abstract][Full Text] [Related]
6. A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.
Vicente C; Arriazu E; Martínez-Balsalobre E; Peris I; Marcotegui N; García-Ramírez P; Pippa R; Rabal O; Oyarzábal J; Guruceaga E; Prósper F; Mateos MC; Cayuela ML; Odero MD
Cancer Lett; 2020 Jan; 468():1-13. PubMed ID: 31593801
[TBL] [Abstract][Full Text] [Related]
7. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
Liu Q; Zhao X; Frissora F; Ma Y; Santhanam R; Jarjoura D; Lehman A; Perrotti D; Chen CS; Dalton JT; Muthusamy N; Byrd JC
Blood; 2008 Jan; 111(1):275-84. PubMed ID: 17761520
[TBL] [Abstract][Full Text] [Related]
8. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Oaks JJ; Santhanam R; Walker CJ; Roof S; Harb JG; Ferenchak G; Eisfeld AK; Van Brocklyn JR; Briesewitz R; Saddoughi SA; Nagata K; Bittman R; Caligiuri MA; Abdel-Wahab O; Levine R; Arlinghaus RB; Quintas-Cardama A; Goldman JM; Apperley J; Reid A; Milojkovic D; Ziolo MT; Marcucci G; Ogretmen B; Neviani P; Perrotti D
Blood; 2013 Sep; 122(11):1923-34. PubMed ID: 23926298
[TBL] [Abstract][Full Text] [Related]
9. ZFP36L2, a novel AML1 target gene, induces AML cells apoptosis and inhibits cell proliferation.
Liu J; Lu W; Liu S; Wang Y; Li S; Xu Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Leuk Res; 2018 May; 68():15-21. PubMed ID: 29518627
[TBL] [Abstract][Full Text] [Related]
10. Honokiol induces proteasomal degradation of AML1-ETO oncoprotein via increasing ubiquitin conjugase UbcH8 expression in leukemia.
Zhou B; Li H; Xing C; Ye H; Feng J; Wu J; Lu Z; Fang J; Gao S
Biochem Pharmacol; 2017 Mar; 128():12-25. PubMed ID: 28043811
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.
Cho EK; Bang SM; Ahn JY; Yoo SM; Park PW; Seo YH; Shin DB; Lee JH
Korean J Intern Med; 2003 Mar; 18(1):13-20. PubMed ID: 12760263
[TBL] [Abstract][Full Text] [Related]
12. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.
Goyama S; Schibler J; Gasilina A; Shrestha M; Lin S; Link KA; Chen J; Whitman SP; Bloomfield CD; Nicolet D; Assi SA; Ptasinska A; Heidenreich O; Bonifer C; Kitamura T; Nassar NN; Mulloy JC
Leukemia; 2016 Mar; 30(3):728-39. PubMed ID: 26449661
[TBL] [Abstract][Full Text] [Related]
13. FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells.
Berdyshev EV; Gorshkova I; Skobeleva A; Bittman R; Lu X; Dudek SM; Mirzapoiazova T; Garcia JG; Natarajan V
J Biol Chem; 2009 Feb; 284(9):5467-77. PubMed ID: 19119142
[TBL] [Abstract][Full Text] [Related]
14. AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia.
Barbetti V; Tusa I; Cipolleschi MG; Rovida E; Dello Sbarba P
Cell Death Dis; 2013 Mar; 4(3):e536. PubMed ID: 23492767
[TBL] [Abstract][Full Text] [Related]
15. Acid ceramidase is upregulated in AML and represents a novel therapeutic target.
Tan SF; Liu X; Fox TE; Barth BM; Sharma A; Turner SD; Awwad A; Dewey A; Doi K; Spitzer B; Shah MV; Morad SA; Desai D; Amin S; Zhu J; Liao J; Yun J; Kester M; Claxton DF; Wang HG; Cabot MC; Schuchman EH; Levine RL; Feith DJ; Loughran TP
Oncotarget; 2016 Dec; 7(50):83208-83222. PubMed ID: 27825124
[TBL] [Abstract][Full Text] [Related]
16. FTY720 induces non-canonical phosphatidylserine externalization and cell death in acute myeloid leukemia.
Young MM; Bui V; Chen C; Wang HG
Cell Death Dis; 2019 Nov; 10(11):847. PubMed ID: 31699964
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically.
Zapotocky M; Mejstrikova E; Smetana K; Stary J; Trka J; Starkova J
Cancer Lett; 2012 Jun; 319(2):144-153. PubMed ID: 22261333
[TBL] [Abstract][Full Text] [Related]
18. [Influence of PP2A activator on proliferation of HL-60 cells and analysis of PP2A activity changes in patients with acute myeloid leukemia].
Yang Y; Li XQ; Huang Q; Huang SA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):594-7. PubMed ID: 21729530
[TBL] [Abstract][Full Text] [Related]
19. FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway.
Li MH; Hla T; Ferrer F
Pediatr Blood Cancer; 2013 Sep; 60(9):1418-23. PubMed ID: 23704073
[TBL] [Abstract][Full Text] [Related]
20. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
